Govt’s push for generic drugs may lead to 5-10% fall in pharmaceutical market value: ICRA
- Matrimony.com to make stock market debut tomorrow
- Cricket: Hardik Pandya’s knock reminded of Kapil Dev, but he still has a long way to go
- ICICI Bank, Prudential said to weigh sale of 6% stake in ICICI Prudential Life
- Donald Trump’s speech to UN General Assembly: What the global media is saying
- Cabinet approves merger of 17 govt presses into 5 units
New Delhi: The government’s push for generic medicines may lead to an estimated 5-10% reduction in value of Indian Pharmaceutical Market (IPM) if only 20% replacement from branded to generic drugs takes place, a report released by ICRA Ltd said.
“It will not be possible to completely eliminate branded drugs. Considering that the prices of unbranded generic drugs are approximately 30-50% cheaper than branded generics, replacing even 20% of the Rs1.15 trillion IPM with such drugs over the medium to long-term could lead to potential 5-10% decline in IPM as well as dent the profitability of Indian pharma companies. However, with operational issues revolving around its successful implementation, the near-term impact is not expected to be significant,” the report said.